These restrictions may be more limiting for compounded products as compared with FDA-approved products regarding efficacy and safety claims.[21] Congress has granted FDA the authority to ensure that prescription drugs are safe and effective for the uses in the drugs labeling and has given FDA the explicit authority to oversee compounded drugs.[22] Under a 1971 Memorandum of Understanding with the FTC, FDA exercises primary responsibility for prescription drug advertising.[23] While compounded medications have different rules for labels, which are written, printed or graphic matter upon the immediate container of a drug[24], compounded drugs are subject to the same FDCA requirements as prescription drugs for labeling, advertising, and promotion.[25] Finally, the APC has asserted that labeling applies to the physical drug container and ancillary written materials (like package inserts)
Here's where most protocols fail: never inject air into the peptide vial to 'equalise pressure'
Generally, yes, but its essential to discuss it with your prescribing doctor
Semaglutide works through the GLP-1 receptor, while tirzepatide works through both GIP and GLP-1 receptor pathways
Consistency during the loading phase matters more than any single high-dose session, since glutathione levels build cumulatively over time
The question of whether semaglutide suppresses appetite immediately comes up frequently